Advertisement
FATE vs IMDX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and IMDX is a Hold.
FATE sees MACD Histogram crosses below signal line
FATE saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 48 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 84 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for IMDX turns negative, indicating new downward trend
IMDX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 83 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IMDX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 45 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMDX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.826) is normal, around the industry mean (67.298). P/E Ratio (-1.638) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. IMDX's P/S Ratio (71.942) is very high in comparison to the industry average of (9.775).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. IMDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
FATE | IMDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 55 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 89 | |
P/E GROWTH RATING 1..100 | 13 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FATE's Valuation (51) in the Biotechnology industry is in the same range as IMDX (63) in the Medical Specialties industry. This means that FATE’s stock grew similarly to IMDX’s over the last 12 months.
FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to IMDX’s over the last 12 months.
FATE's SMR Rating (98) in the Biotechnology industry is in the same range as IMDX (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to IMDX’s over the last 12 months.
FATE's Price Growth Rating (65) in the Biotechnology industry is in the same range as IMDX (89) in the Medical Specialties industry. This means that FATE’s stock grew similarly to IMDX’s over the last 12 months.
IMDX's P/E Growth Rating (9) in the Medical Specialties industry is in the same range as FATE (13) in the Biotechnology industry. This means that IMDX’s stock grew similarly to FATE’s over the last 12 months.
| FATE | IMDX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 11 days ago 87% | 6 days ago 79% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while IMDX’s FA Score has 1 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- IMDX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while IMDX’s TA Score has 4 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- IMDX’s TA Score: 4 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а -30.25% price change this week, while IMDX (@Medical Specialties) price change was -14.06% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.79%. For the same industry, the average monthly price growth was -7.29%, and the average quarterly price growth was +34.42%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
IMDX is expected to report earnings on Nov 16, 2026.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (-1.79% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
FATE and
Correlation & Price change
A.I.dvisor indicates that over the last year, FATE has been loosely correlated with CABA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then CABA could also see price increases.
| Ticker / NAME | Correlation To FATE | 1D Price Change % | ||
|---|---|---|---|---|
| FATE | 100% | -4.48% | ||
| CABA - FATE | 47% Loosely correlated | -3.76% | ||
| NKTX - FATE | 45% Loosely correlated | -5.93% | ||
| VCYT - FATE | 44% Loosely correlated | -1.22% | ||
| SANA - FATE | 43% Loosely correlated | +0.50% | ||
| FDMT - FATE | 42% Loosely correlated | +0.95% | ||
More | ||||
IMDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMDX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMDX jumps, then STRRP could also see price increases.
| Ticker / NAME | Correlation To IMDX | 1D Price Change % | ||
|---|---|---|---|---|
| IMDX | 100% | -7.36% | ||
| STRRP - IMDX | 37% Loosely correlated | N/A | ||
| FATE - IMDX | 31% Poorly correlated | -4.48% | ||
| NEPH - IMDX | 30% Poorly correlated | -7.85% | ||
| GOSS - IMDX | 29% Poorly correlated | -2.40% | ||
| BMRN - IMDX | 29% Poorly correlated | +0.93% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SVAL | 42.41 | 0.03 | +0.07% |
| iShares US Small Cap Value Factor ETF (SVAL) | |||
| WDAF | 30.58 | N/A | N/A |
| WisdomTree Asia Defense Fund | |||
| RJMI | 24.75 | -0.05 | -0.22% |
| RJ Eagle Municipal Income ETF (RJMI) | |||
| SCHK | 36.24 | -0.14 | -0.38% |
| Schwab 1000 Index ETF (SCHK) | |||
| EMEQ | 57.03 | -0.55 | -0.96% |
| Nomura ETF Trust Nomura Focused Emerging Markets Equity ETF (EMEQ) | |||